Cambridge, UK and Perray-en-Yvelines, France - 27th August 2026 - Domainex, a leading integrated drug discovery services partner and Tebu-Bio, a leading European distributor of high-quality life science research products and services, today announced an umbrella licensing agreement for streamlined access to 700+ validated Cytion cell lines, without the licensing complexity that can delay outsourced programmes.
For customers, the benefit is clear: a broad, high-quality cell-line portfolio available through a flat, transparent fee structure, with no hidden licence costs that can otherwise add tens of thousands to a project. This gives teams greater budget certainty, faster project initiation and the flexibility to select the most appropriate biological models without being constrained by opaque or case-by-case licensing terms.
The expanded collection includes widely used cell lines such as MCF-7, THP-1, HEK293 and A549, alongside specialised, application-specific models spanning lung, breast, colon, liver, pancreas, brain, bone, skin, vascular and immune tissues. With models supporting oncology, fibrosis, inflammation, neuroscience, regenerative medicine and more, Domainex can help customers match the right cellular system to the right scientific question from the outset.
Integrated into Domainex’s end-to-end drug discovery platform, this enhanced cell-line access supports target validation, functional biology, assay development, phenotypic and target-based screening, mechanism-of-action studies, biomarker research, hit identification and lead optimisation. By combining scientific breadth with simple commercial terms, Domainex enables CRO customers to accelerate decision-making, reduce administrative friction and move from biological hypothesis to robust data generation with confidence.
For further information, please contact:
Domainex: enquires@domainex.co.uk
Tebu-Bio: Contact form - Tebubio
Notes to editors
About Domainex:
Domainex is a leading, multi-award-winning, integrated medicines research service partner which provides tailored discovery solutions from target expression to the identification of pre-clinical candidates.
Our world-leading experts accelerate research projects by combining a problem-solving approach with cutting-edge technologies such as PureDiscTM and Direct-to-Biology. With deep expertise across a wide range of target classes and therapeutic areas, and a core focus on the hit identification and hit-to-lead stages, we deliver high-quality results that support confident, timely decision-making for our partners. Domainex operates from state-of-the-art facilities in Cambridge, UK.
Further information about Domainex and its award-winning lead discovery services can be found at www.domainex.co.uk.
About Tebu-Bio:
Tebu‑Bio is a pan‑European life sciences supplier and CRO partner providing researchers with ethically sourced biological reagents and specialised laboratory services. Founded in 1953, the company now operates across nine European sites and offers access to more than 1.3 million research‑grade products.
Key focus areas:
- Biological Reagents: antibodies, proteins, cells, assays, chemicals, mRNA tools, and custom solutions.
- CRO Services: mRNA production, cell line engineering, protein production, in vitro models, biomarker analysis, and biostatistics.
- Procurement Support: compliant sourcing, logistics, and purchasing integrations.